文献速递骨软组织肉瘤与黑色素瘤

抗PD-1抗体单药与抗PD-1联合抗CTLA-4作为晚期肢端黑色素瘤一线免疫治疗的疗效比较:254例日本患者的回顾性多中心研究

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
PubMed 文献 · Eur J Cancer · 2022-10-01

该回顾性多中心研究纳入2014至2020年日本24家机构254例晚期肢端黑色素瘤患者,比较抗PD-1单药与抗PD-1联合抗CTLA-4一线免疫治疗的疗效。掌跖黑色素瘤患者中两组客观缓解率、无进展生存和总生存无显著差异;甲下黑色素瘤患者中联合组客观缓解率显著更高,联合治疗是无进展生存的独立预测因素。

要点

  • 掌跖黑色素瘤中抗PD-1联合抗CTLA-4的客观缓解率、无进展生存和总生存与单药无显著差异。
  • 甲下黑色素瘤中联合组客观缓解率61%显著高于单药组10%(P < 0.001)。
  • 甲下黑色素瘤中联合治疗是无进展生存的独立预测因素(P = 0.002)。

核心结论

  • 对于晚期掌跖黑色素瘤,抗PD-1联合抗CTLA-4的疗效不优于抗PD-1单药。
  • 对于晚期甲下黑色素瘤,抗PD-1联合抗CTLA-4可能比抗PD-1单药更有效。

研究设计与样本

  • 回顾性多中心研究,纳入2014至2020年日本24家机构接受抗PD-1单药或抗PD-1联合抗CTLA-4作为一线免疫治疗的晚期肢端黑色素瘤患者。
  • 共254例患者,其中掌跖黑色素瘤180例,甲下黑色素瘤74例。

主要发现

  • 掌跖黑色素瘤患者中,抗PD-1单药组与联合组的客观缓解率分别为19%与31%(P = 0.44),无进展生存分别为5.9个月与3.2个月(P = 0.74),总生存分别为23.1个月与未达到(P = 0.55),均无显著差异。
  • 甲下黑色素瘤患者中,联合组客观缓解率61%显著高于单药组10%(P < 0.001)。
  • 甲下黑色素瘤患者中,联合组无进展生存6.4个月,单药组3.8个月(P = 0.10)。
  • Cox多因素分析显示,抗PD-1联合抗CTLA-4是甲下黑色素瘤患者良好无进展生存的独立预测因素(P = 0.002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. METHODS: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. RESULTS: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). CONCLUSIONS: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nakamura Y, Namikawa K, Kiniwa Y, et al. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients. Eur J Cancer. 2022. PMID: 36194906. doi:10.1016/j.ejca.2022.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。